

Status report on Part D

ISSUE: In this session, staff will provide information on beneficiaries' access to medications and program costs, and discuss the role of competition in Part D.

KEY POINTS: We will review information about the numbers of stand-alone and Medicare Advantage prescription drug plans participating in Part D for 2017 and the types of benefit designs they offer, the number of plans available to individuals receiving the low-income subsidy as premium free. We will also discuss trends in indicators of program operations, including market structure, drug pricing, aggregate spending levels, access and quality.

ACTION: Commissioners should provide comments on the scope and substance of this analysis.

STAFF CONTACT: Shinobu Suzuki and Rachel Schmidt (202-220-3700)